PUK27 ERYTHROPOIESIS-STIMULATING AGENT DOSING AND HEMOGLOBIN TRENDS OVER TIME IN CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS  by Lafeuille, MH et al.
Abstracts A81
notes, and discussions with on-site health care professionals. RESULTS: The ﬁnal 
sample included 100 clinics, with an average of 73.4 patients per unit. CMS provided 
estimated CMAs for 89 of these units. In 75 of 89 clinics, the case mix adjuster 
detected in the study was lower than that ascertained by CMS (mean difference = 
0.09). In 14 units, the CMA was higher than reported by CMS (mean difference = 
0.04). The average CMA for the 89 units was 1.21 versus 1.28 reported by CMS for 
these same units, with uneven geographic distribution on the difference. The inability 
to replicate CMS CMAs would result in a 7% decrease in payment, with a differential 
from CMS projected payments of > $350 million over a 4 year period. CONCLU-
SIONS: Without access to Medicare claims data, we were unable to replicate CMS 
CMAs, representing the potential for signiﬁcant underpayment for dialysis units under 
the proposed prospective payment system.
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BACKGROUND In 2011, a new prospective payment system will be instituted for 
Medicare payments for dialysis. Payments will be calculated per session. It is unclear 
how long-acting medications will fare under this new system, i.e., if patients are 
administered a monthly medication and then miss subsequent sessions, how will this 
impact revenue? OBJECTIVES: Model reimbursement for one long-acting drug under 
the proposed bundled payment system from the provider perspective. METHODS: 
We assumed that there would be one set of case mix adjusters (CMAs) and outlier 
payment for all currently separately billables; that monthly drugs are truly adminis-
tered only once per month; and that all payments are made in full, i.e., all 20% co-pays 
are made in full. We included 3 levels of drug utilization (for one drug) and 3 levels 
of other resource utilization, each ranging from 33% below to 33% above the current 
mean reported by CMS. We included 4 levels of rebates ranging from 0% to 50%. 
We examined 16 different CMAs, ranging from 0.6 to 3.6 in increments of 0.2. We 
varied the number of dialysis sessions in a month from 1 to 13. This 3 × 3 × 4 × 16 
× 13 matrix produced 7488 solutions. RESULTS: The model showed providers will 
incur losses when a patient receives a full drug dose in 1 session and misses all sub-
sequent sessions, unless manufacturers provide signiﬁcant rebates/price reductions. 
Losses occur even at 50% discounts when CMAs fall below 0.80. Greatest losses do 
not always occur when there is only 1 session in a month, but can occur at 2 to 7 
sessions (J-shaped curve). CONCLUSIONS: Losses on long-acting medications will 
occur, but can be mitigated and in some cases eliminated through manufacturer pricing 
discounts. However, the relationship between component costs, CMA and session 
number are non-linear.
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OBJECTIVES: This study evaluated dosing trends and hemoglobin levels over time in 
patients with chronic kidney disease (CKD) not on dialysis receiving epoetin alfa 
(EPO) or darbepoetin alfa (DARB), 2 erythropoiesis-stimulating agents (ESAs). 
METHODS: An analysis of medical claims between July 2000 and March 2009 from 
the Ingenix IMPACT database was conducted. Patients ³18 years, newly initiated on 
ESAs, with ³1 claim for CKD were included. Patients diagnosed with cancer, receiving 
chemotherapy or dialysis, or receiving both agents were excluded. Average weekly 
ESA dose, weighted by the treatment duration, was calculated and reported by semes-
ter to evaluate trends over time. For the subset of patients with laboratory data, 
semi-annual mean of baseline and achieved hemoglobin levels were assessed over time. 
RESULTS: A total of 4,182 ESA-treated patients were identiﬁed (EPO 2684; DARB 
1,498). Mean age was 64.2 and 63.2 in EPO and DARB groups, respectively, whereas 
proportion of women was 51% and 55%. The mean weekly dose was relatively stable 
for both ESAs over time (EPO: mean: 10,652 units; median: 10,623 units; 25th–75th 
percentiles: 9,872- 11,609 units; DARB: mean: 41 mcg; median: 42 mcg; 25th–75th 
percentiles: 38–43 mcg); however, a slight decreasing trend was observed in more 
recent years (2006–2008). Analysis of laboratory results revealed a declining trend in 
mean baseline hemoglobin over time (10.5 g/dL in 2003S1 vs. 10.1 g/dL in 2008S2) 
consistent with recent treatment guidelines. A decreasing trend was also observed in 
mean achieved hemoglobin during the treatment episode (11.9 g/dL in 2003S1 vs. 
10.9 g/dL in 2008S2). Furthermore, the proportion of patients with achieved hemo-
globin >12 g/dL decreased from 41% before April 2006 to 23% in April 2007, after 
the KDOQI guidelines changed. CONCLUSIONS: This analysis of data from CKD 
patients not on dialysis reported relatively stable ESA dosing trends and decreasing 
trend in hemoglobin levels during the study period.
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OBJECTIVES: To compare the utilization of epoetin alfa (EPO) and darbepoetin alfa 
(DARB), 2 erythropoiesis-stimulating agents (ESAs), in chronic kidney disease (CKD) 
patients not receiving dialysis before and after the National Kidney Foundation/Kidney 
Disease Outcomes Quality Initiative (KDOQI) Anemia Treatment Guideline changes 
in March 2007. METHODS: An analysis of medical claims from Ingenix IMPACT 
(2006–2008) and Medicare 5% (2006–2007) databases was conducted. Patients ≥18 
years, newly initiated on ESAs, with ≥1 claim for CKD were included. Patients diag-
nosed with cancer, receiving chemotherapy or dialysis, or receiving both agents were 
excluded. Patients initiating ESA prior to March 31, 2007 were classiﬁed into the 
pre-guideline changes group and compared with patients initiating ESA after March 
31, 2007 using the same time window prior and after KDOQI guideline changes. Dose 
per injection and cumulative dose evaluated up to 16 weeks after treatment initiation 
were compared. RESULTS: A total 3427 patients were identiﬁed from both data 
sources. Following guideline changes, a lower number of patients initiated ESAs 
changes in the IMPACT database (1,059 pre- vs. 518 post-guideline changes) while 
the number of ESA-treated patient was more stable in the Medicare database (875 
pre- vs. 975 post-guideline change). Among ESA-treated patients, the mean number 
of injections per patient decreased after the KDOQI guideline changes (pre- versus 
post-guideline changes: IMPACT—EPO: 4.0 vs. 3.8; DARB: 2.9 vs. 3.1; Medicare—
EPO: 5.4 vs. 5.1; DARB: 4.9 vs. 4.6). Mean cumulative dose administered per patient 
also decreased post-KDOQI guideline changes [IMPACT—EPO Units: 95,147 vs. 
86,898 (9% decrease) for pre- versus post-guideline changes, DARB mcg: 374 vs. 340 
(9% decrease); Medicare—EPO Units: 104,739 vs. 103,265 (15% decrease), DARB 
mcg: 557 vs. 520 (4% decrease)]. CONCLUSIONS: This observational study suggests 
that the recent KDOQI guideline changes impacted the ESA utilization patterns in 
CKD patients not receiving dialysis. A trend toward decreased ESA utilization was 
observed.
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OBJECTIVES: Current efforts to inﬂuence health care using comparative effectiveness 
research (CER) often miss the opportunity to incorporate patient and consumer per-
spectives. The Center for Medical Technology Policy (CMTP) seeks to generate evi-
dence for decision-makers and recognizes the importance of including patients and 
consumers as fellow decision-makers. This paper reports on the formation of and 
recommendations from a Patient and Consumer Advisory Committee (PCAC) for 
CMTP. METHODS: Following a literature review on consumer advocacy in health 
and interviews with experts regarding appropriate structure and training for effective 
patient and consumer engagement in CER, CMTP convened a workgroup of consumer 
and patient advocates to review practices and create a set of recommendations for 
strengthening the patient and consumer voice in CMTP’s prioritization of technologies 
and development of guidelines for CER study designs. RESULTS: The workgroup’s 
key recommendations for technology prioritization include 1) how and when to solicit 
input on technology topics from patient/consumer groups; 2) the role of patients/
consumers in setting priorities that reﬂect public values; 3) the information require-
ments of patients / consumers to serve as effective public representatives; and 4) the 
characteristics of patients/consumers that would contribute a broad perspective. For 
the development of study design guidelines, 1) gather patient/consumer information 
preferences via semi-structured interviews; 2) address patient/consumer identiﬁed out-
comes; 3) consider having advocates who are also subject-matter experts review and 
comment on summaries from stakeholder meetings in addition to the public represen-
tatives who directly participate; and 4) consult with patient/consumer advocates about 
the suitability of disseminating project ﬁndings. CONCLUSIONS: As CER has 
expanded, a clear need has emerged for guidance on engaging public representatives 
in this area. There is a risk that the public’s voice will be lost in the CER enterprise 
unless action is taken to champion and bring it to the forefront of the discussion.
